KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest Expenses (2018 - 2025)

Historic Interest Expenses for Vertex Pharmaceuticals (VRTX) over the last 10 years, with Q3 2025 value amounting to $3.3 million.

  • Vertex Pharmaceuticals' Interest Expenses fell 5600.0% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.8 million, marking a year-over-year decrease of 6666.67%. This contributed to the annual value of $30.6 million for FY2024, which is 3061.22% down from last year.
  • According to the latest figures from Q3 2025, Vertex Pharmaceuticals' Interest Expenses is $3.3 million, which was down 5600.0% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Interest Expenses ranged from a high of $11.2 million in Q2 2023 and a low of $2.8 million during Q4 2024
  • In the last 3 years, Vertex Pharmaceuticals' Interest Expenses had a median value of $8.7 million in 2024 and averaged $7.3 million.
  • The largest annual percentage gain for Vertex Pharmaceuticals' Interest Expenses in the last 5 years was 1160.71% (2024), contrasted with its biggest fall of 7358.49% (2024).
  • Vertex Pharmaceuticals' Interest Expenses (Quarter) stood at $10.6 million in 2023, then tumbled by 73.58% to $2.8 million in 2024, then grew by 17.86% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.7 million for Q2 2025, and $3.0 million during Q1 2025.